Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Popular weight loss drugs promise to slim waistlines and improve our general health, but they also come with some unpleasant ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A new gene risk score, informed by machine learning, can predict weight-loss outcomes after Roux-en-Y gastric bypass surgery.

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...